Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in acute myelogenous leukemia

R P Gale

    Cancer Treatment Reports
    |January 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Recent advances in acute myelogenous leukemia (AML) treatment show intensive chemotherapy induces remission in most patients. However, further treatments to prolong remissions have shown limited success, though some patients achieve long-term remission or cure.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program.

    Blood·2001
    Same author

    Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission.

    Blood·2000
    Same author

    Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County.

    Leukemia research·2000
    Same author

    Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

    Blood·2000
    Same author

    T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities.

    Blood·2000
    Same author

    Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia.

    Blood·2000
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Medicine

    Background:

    • Acute myelogenous leukemia (AML) is a significant hematologic malignancy.
    • Chemotherapy remains a cornerstone of AML treatment.

    Purpose of the Study:

    • To review recent progress in AML treatment.
    • To evaluate the efficacy of intensive induction chemotherapy and subsequent treatment modalities.

    Main Methods:

    • Review of recent clinical studies and treatment data for acute myelogenous leukemia.
    • Analysis of remission rates and duration following intensive induction chemotherapy.

    Main Results:

    • Intensive induction chemotherapy (cytarabine, daunorubicin, +/- 6-thioguanine) achieves remission in over 70% of AML patients.

    Related Experiment Videos

  • Median remission duration is typically 1-2 years.
  • Maintenance chemotherapy, immunotherapy, and CNS prophylaxis have not convincingly prolonged remissions.

    • Conclusions:

    • Intensive induction chemotherapy is effective in achieving initial remissions in AML.
    • Current strategies to prolong remissions beyond induction therapy have limited demonstrated benefit.
    • A subset of AML patients may experience long-term remission or potential cure.